Immunoglobulin E and bullous pemphigoid

被引:0
作者
Emanuele Cozzani
Giulia Gasparini
Giovanni Di Zenzo
Aurora Parodi
机构
[1] San Martino Policlinic Hospital,Di.S.Sal, Section of Dermatology, University of Genoa
[2] Fondazione Luigi Maria Monti,Molecular and Cell Biology Laboratory
[3] IDI-IRCCS,undefined
来源
European Journal of Dermatology | 2018年 / 28卷
关键词
bullous pemphigoid; Th2; anti-BP230 and anti-BP180 IgE; omalizumab;
D O I
暂无
中图分类号
学科分类号
摘要
Clinical features and histological findings in bullous pemphigoid (BP) suggest a Th2-oriented inflammatory reaction, especially in the early stages of the disease. Elevated total serum IgE levels, blood eosinophilia, and elevated serum levels of different soluble inflammatory Th2 response mediators have been described in large cohorts of patients with classic clear-cut BP manifestations. Direct immunofluorescence, indirect immunofluorescence, and anti-BP230 and anti-BP180 IgE ELISA testing show self-reactive IgE autoantibodies in a consistent number of BP patients. Both IgE autoantibodies and a Th2-oriented immune response may play a role in the initial phases of BP and atypical cases of BP, such as severe erythematous and urticarial forms of BP, as well as blister formation. Two recently reported experimental murine models employing IgE autoantibodies against BP180 have been reported and the successful treatment of bullous pemphigoid with the anti-IgE antibody, omalizumab, supports the roles played by IgE autoantibodies in BP pathogenesis.
引用
收藏
页码:440 / 448
页数:8
相关论文
共 50 条
[31]   The pathophysiology of bullous pemphigoid [J].
Kasperkiewicz, Michael ;
Zillikens, Detlef .
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2007, 33 (1-2) :67-77
[32]   When Bullous Pemphigoid Is Not Bullous Pemphigoid: The Importance of Going Beyond Direct Immunofluorescence [J].
Hopkins, Christina R. ;
Ren, Vicky ;
Grover, Raminder ;
Cockerell, Clay ;
Hsu, Sylvia .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (02)
[33]   Bullous scabies and bullous pemphigoid triggered by scabies [J].
Bornhövd, E ;
Partscht, K ;
Flaig, MJ ;
Messer, G .
HAUTARZT, 2001, 52 (01) :56-61
[34]   Research progress of omalizumab in the treatment of bullous pemphigoid [J].
Ling, Xiaoya ;
Shou, Xinyang ;
Lou, Yufei ;
Ling, Jie ;
Zhang, Mengyuan ;
Yu, Tugen ;
Gu, Weijia .
JOURNAL OF DERMATOLOGY, 2023, 50 (05) :575-587
[35]   Bullous pemphigoid in a leg affected with hemiparesia: a possible relation of neurological diseases with bullous pemphigoid? [J].
Foureur, N ;
Descamps, V ;
Lebrun-Vignes, B ;
Picard-Dahan, C ;
Grossin, M ;
Belaich, S ;
Crickx, B .
EUROPEAN JOURNAL OF DERMATOLOGY, 2001, 11 (03) :230-233
[36]   Bullous pemphigoid with a prolonged prodrome [J].
Nakatani, Tomomi ;
Inaoki, Makoto ;
Takehara, Kazuhiko .
JOURNAL OF DERMATOLOGY, 2008, 35 (07) :433-436
[37]   Bullous pemphigoid induced by vildagliptin [J].
Lopez-Sanchez, Geraldine ;
Reyna-Villasmil, Eduardo .
AVANCES EN BIOMEDICINA, 2016, 5 (01) :46-49
[38]   Bullous pemphigoid associated with silicosis [J].
Ueki, H ;
Kohda, M ;
Hashimoto, T ;
Komai, A ;
Nobutoh, T ;
Yamaguchi, M ;
Ohmori, K ;
Miyashita, F ;
Yoda, N .
DERMATOLOGY, 2000, 201 (03) :265-267
[39]   Nodular Subtype of Bullous Pemphigoid [J].
Dangel, Bjoern ;
Kofler, Lukas ;
Metzler, Gisela .
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2016, 20 (06) :570-572
[40]   Bullous pemphigoid and hypercoagulability: a review [J].
Zhang, Bingjie ;
Yang, Nan ;
Li, Li .
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2025, 21 (03) :323-332